Factbox-New recommendations for weight-loss drugs
By Patrick Wingrove
Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novo Nordisk’s Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with a body mass index (BMI) of 27 or more who have at least one weight-related ailment, or in any patient with a BMI of 30 or greater.
(Reuters) - As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. That is where the debate begins. | 11:22am
(Reuters) - Novo Nordisk's Wegovy won U.S. approval in June 2021 with a label that says it can be used for chronic weight management in patients with a body mass index (BMI) of 27 or more who have at least one weight-related ailment, or in any patient with a BMI of 30 or greater. | 07:09am
Should they be used broadly, along with diet and exercise? Or should higher risk patients with other conditions be prioritized?